At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 01-30 16:00:00 EST
0.5597
-0.0201
-3.47%
盘后0.5500
-0.0097-1.73%
19:13 EST
High0.6000Low0.5470Vol158.66K
Open0.5724D1 Closing0.5798Amplitude9.14%
Mkt Cap11.94MTradable Cap9.38MTotal Shares21.33M
T/O88.52KT/O Rate0.95%Tradable Shares16.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron granted Japan patent for potency assay methods for MSCs
TIPRANKS  ·  01-29
Longeveron granted Japan patent for potency assay methods for MSCs
Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells
Reuters  ·  01-29
Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells
Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout
TIPRANKS  ·  01-26
Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout
Longeveron Inc - Elpis Ii Trial Results Anticipated in Q3 2026
THOMSON REUTERS  ·  01-26
Longeveron Inc - Elpis Ii Trial Results Anticipated in Q3 2026
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire  ·  01-26
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
GlobeNewswire  ·  2025-12-29
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using Its Proprietary Stem Cell Therapy
THOMSON REUTERS  ·  2025-12-17
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using Its Proprietary Stem Cell Therapy
Longeveron Granted U.S. Patent for Stem Cell Therapy to Treat Female Sexual Dysfunction
Reuters  ·  2025-12-17
Longeveron Granted U.S. Patent for Stem Cell Therapy to Treat Female Sexual Dysfunction
Longeveron Executives Speak at Global CardioVascular Clinical Trialists Forum
Reuters  ·  2025-12-03
Longeveron Executives Speak at Global CardioVascular Clinical Trialists Forum
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum
THOMSON REUTERS  ·  2025-12-03
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum
Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy
Reuters  ·  2025-12-02
Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging
THOMSON REUTERS  ·  2025-12-02
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging
Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows
Reuters  ·  2025-12-02
Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows
Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
THOMSON REUTERS  ·  2025-12-02
Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease
Reuters  ·  2025-11-19
Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
THOMSON REUTERS  ·  2025-11-19
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
Longeveron granted U.S. patent for administration of MSCs
TIPRANKS  ·  2025-11-12
Longeveron granted U.S. patent for administration of MSCs
Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
Reuters  ·  2025-11-12
Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy
THOMSON REUTERS  ·  2025-11-12
Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy
Longeveron Inc - Patent Rights in U.S. Through 2038
THOMSON REUTERS  ·  2025-11-12
Longeveron Inc - Patent Rights in U.S. Through 2038

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--